31results about How to "Induce weight loss" patented technology

Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon / GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (K-RNRNNIA) and SEQ ID NO: 28 (KRNR).

Methods and therapeutics are provided for treating metabolic disorders by activation of melanocortin signaling pathways. Generally, the methods and therapeutics can induce activation of melanocortin receptor signaling to increase energy expenditure and induce weight loss. In one embodiment, a method for performing a diagnostic procedure can be chosen, energy expenditure then assess in light of the diagnostic procedure and a definitive procedure(s) can be selected dependent on the outcome of the energy assessment. In another embodiment, a diagnostic procedure can be chosen to activate melanocortin receptor pathways, energy expenditure can be assessed and a definitive procedure(s) can be chosen that selectively and optimally activate melanocortin receptor pathways.

The present application provides devices and methods for inducing weight loss. In particular, the present application provides devices which are secured in the stomach or external to the stomach to reduce digestion and / or absorption of food in accordance with the methods of the invention

Method and system to provide therapy for obesity, gastric motility, or to induce weight loss comprises ablating the gastric tissue around the “pacemaker” region of the stomach, and electrically pacing the stomach with a pulse generator / stimulator to control the electrical activity of the gastric muscle. The ablation to the gastric tissue may be from the epigastric side, or may be from inside the stomach. The ablation may be performed utilizing any one of: radiofrequency catheter ablation; radiofrequency catheter ablation using an irrigated tip catheter; microwave ablation; cryoablation; high intensity focused ultrasound (HIFU) ablation; and laser ablation. The ablation of the “pacemaker” region of the stomach may be partial or complete. A gastric pulse generator / stimulator is implanted to provide electrical pulses to the stomach. The function of the gastric stimulator after complete ablation of the pacemaker region, is to provide a basic electrical rhythm (BER) to regulate and control electrical activity of the stomach. Alternatively, if partial ablation is performed the function of the gastric pulse generator / stimulator is to enhance the residual basic electrical rhythm (BER), or to interfere with the residual basic electrical rhythm (BER).

Medical devices and methods are provided for forming an intestinal bypass anastomosis, such as for treatment of obesity. The medical devices and methods are minimally invasive and reduce complications. Two magnet assemblies are deployed in a spaced apart relationship, and are transluminally brought together to approximate the tissue and form an anastomosis therebetween.

Modified glucagon peptides are disclosed having improved solubility and / or half-life while retaining glucagon agonist activity. The glycogen peptides have been modified by substitution of native amino acids with, and / or addition of, charged amino acids to the carboxy terminus of the peptide. The modified glucagon agonists can be further modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 23, or both to further enhance the solubility of the glucagon agonist analogs.

Apparatus for treating a patient is provided, including an electrode device, which is configured to be placed in a vicinity of at least one gall bladder site of the patient selected from the group consisting of: a gall bladder, a neck of the gall bladder, a cystic duct, a hepatic duct, a common hepatic duct, a bile duct, a common bile duct, sensory fibers of the gall bladder, and a hepatic port. The apparatus further includes a control unit, which is configured to drive the electrode device to apply a current to the site, and to configure the current to induce weight loss of the patient. Other embodiments are also described.

Methods and therapeutics are provided for treating metabolic disorders by activation of melanocortin signaling pathways. Generally, the methods and therapeutics can induce activation of melanocortin receptor signaling to increase energy expenditure and induce weight loss. In one embodiment, a method for performing a diagnostic procedure can be chosen, energy expenditure then assess in light of the diagnostic procedure and a definitive procedure(s) can be selected dependent on the outcome of the energy assessment. In another embodiment, a diagnostic procedure can be chosen to activate melanocortin receptor pathways, energy expenditure can be assessed and a definitive procedure(s) can be chosen that selectively and optimally activate melanocortin receptor pathways.

A method for inducing weight loss in a patient, the method comprising:intentionally occluding a blood vessel so as to create hypoperfusion in a gastrointestinal organ serviced by the blood vessel, whereby to interfere with normal gastrointestinal function and thereby induce weight loss in a patient.

The present invention provides for the use of combinations of drugs to treat addictive disorders. More specifically, the present invention relates the use of drugs in conjunction with behavioral intervention to treat alcohol-related diseases and disorders as well as treatment of obesity and regulating weight.

The invention provides methods for treating diabetes or obesity, as well as methods for inducing weight loss, preventing weight gain, or controlling weight in a patient in need thereof. The methods comprise administering to the patient at least one effective dose of a GLP-1 receptor agonist, or a regimen of GLP-1 receptor agonist comprising a plurality of substantially evenly spaced doses. The effective dose or regimen does not induce substantial nausea or appetite suppression in the patient.

This invention relates to substituted imidazole derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.

The present invention relates to methods for increasing the suppression of hunger and / or increasing the reduction of prospective consumption and / or increasing the reduction of appetite and / or increasing the feeling of satiety and / or reducing non-fat energy uptake in the gastrointestinal tract of a mammal in order to prevent a positive non-fat energy balance, weight gain, over-weight and obesity, and to induce a negative non-fat energy balance and weight loss in subjects who wish to reduce their body weight. In particular, feed, food and / or beverages and dietary supplements of the present invention comprises mucilage such as flax seed mucilage and / or one or more active compounds of mucilage useful for increasing the suppression of hunger and / or increasing the reduction of prospective consumption and / or increasing the reduction of appetite and / or increasing the feeling of satiety and / or reducing the digestibility of non-fat energy in the gastrointestinal tract of a mammal.

The present application provides methods and devices for inducing weight loss. In particular, the present application provides methods for modifying a duodenum to induce weight loss.

Weight loss agents include compounds defined by Formula I or a pharmaceutically acceptable salt or prodrug thereof, compositions containing the same, and methods of use thereof are described herein. In some embodiments, the compound is Withaferin A. In other embodiments, the compound is Michael addition product of Withaferin A. The compounds can be administered to induce weight loss in a pre-obese, obese, or morbidly obese patient, reduce body fat in a pre-obese, obese, or morbidly obese patient, reduce food intake in a pre-obese, obese, or morbidly obese patient, improve glucose homeostasis in a pre-obese, obese, or morbidly obese patient, or combinations thereof.

A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula (II), wherein R1 and R2, the same or different from each other, are H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, —CH2CORS, —CH2C(O)NRS, —C(O)R5, or —CH2OR5, and can optionally contain halogen atoms, where R5 is a C1-C12 alkyl group. R3 and R4, the same or different from each other, are H, C1-C20 alkyl cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl.

Medical devices and methods are provided for forming an intestinal bypass anastomosis, such as for treatment of obesity. The medical devices and methods are minimally invasive and reduce complications. Two magnet assemblies are deployed in a spaced apart relationship, and are transluminally brought together to approximate the tissue and form an anastomosis therebetween.

This disclosure relates to the field of GLP-1R and GCGR agonists, formulations, and methods of using the same, including but not limited to dual agonist peptides of any of SEQ ID NOS. 1-10 or 12-27 conjugated to a non-ionic glycolipid surfactant.

The present application provides devices and methods for inducing weight loss. In particular, the present application provides devices which are secured in the stomach or external to the stomach to reduce digestion and / or absorption of food in accordance with the methods of the invention.

This invention relates to 1,5,6,7-tetrahydropynolo[3,2-c]pyridine derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.

Administration of estrogenic extracts having ERα-agonistic activity results in reduced fat accumulation, induced weight loss, or both.

HSP 90 inhibitors for the promotion of weight loss, as well as formulations containing these inhibitors and methods of using thereof, are described herein. Also provided are pharmaceutical compositions containing a therapeutically effective amount of a weight loss agent, or a pharmaceutically acceptable salt or prodrug thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical compositions can be administered to induce weight loss in a pre-obese, obese, or morbidly obese patient, reduce body fat in a pre-obese, obese, or morbidly obese patient, reduce food intake in a pre-obese, obese, or morbidly obese patient, improve glucose homeostasis in a pre-obese, obese, or morbidly obese patient, or combinations thereof. In particular embodiments, the weight loss agent is co-administered with leptin or a leptin analog.

A pharmaceutical diluent and a compound of formula VI: wherein: R10=H, or C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing halogen atoms; R11=H3 or C]-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing halogen atoms; R12=H, or C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing halogen atoms, —C(O)R13, where R13 is H, Ci-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing halogen atoms, or —OH, —OR14 or —NR14, where R14 is H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing halogen atoms.

The invention provides methods for treating diabetes or obesity, as well as methods for inducing weight loss, preventing weight gain, or controlling weight in a patient in need thereof. The methods comprise administering to the patient at least one effective dose of a GLP-1 receptor agonist, or a regimen of GLP-1 receptor agonist comprising a plurality of substantially evenly spaced doses. The effective dose or regimen does not induce substantial nausea or appetite suppression in the patient.

Pentacyclic triterpene compounds are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the compounds, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The compounds can also be co-administered with leptin or a leptin analog.

The present invention relates to a pharmaceutical composition comprising a tetrahydrocannabivarin (THCV), wherein the composition further comprises cannabigerol (CBG) or cannabinodiol (CBND) or a mixture thereof, for use in the prevention and treatment of overweight, preferably associated with obesitas. The pharmaceutical composition according to the invention may further comprise the following additional compounds tetrahydrocannabinol (THC), or Cannabigerol (CBG) or Cannabinodiol (CBND) or a combination thereof.

Methods are provided for administering an extended half-life GLP-1 / GIP coagonist peptide to a patient in need thereof for reducing weight gain, inducing weight loss, treating hyperglycemia, reducing blood glucose levels, or normalizing blood glucose levels in said patient.

Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The weight loss agents can also be co-administered with leptin or a leptin analog.